- Home
- YSXT vs AVTX Comparison
YSXT vs AVTX Comparison
Compare YSXT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSXT
- AVTX
- Stock Information
- Founded
- YSXT 2011
- AVTX 2011
- Country
- YSXT China
- AVTX United States
- Employees
- YSXT N/A
- AVTX N/A
- Industry
- YSXT Automotive Aftermarket
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- YSXT Consumer Discretionary
- AVTX Health Care
- Exchange
- YSXT Nasdaq
- AVTX Nasdaq
- Market Cap
- YSXT 87.9M
- AVTX 88.4M
- IPO Year
- YSXT 2024
- AVTX 2015
- Fundamental
- Price
- YSXT $2.50
- AVTX $7.35
- Analyst Decision
- YSXT
- AVTX Strong Buy
- Analyst Count
- YSXT 0
- AVTX 4
- Target Price
- YSXT N/A
- AVTX $33.00
- AVG Volume (30 Days)
- YSXT 72.8K
- AVTX 54.4K
- Earning Date
- YSXT 01-01-0001
- AVTX 03-28-2025
- Dividend Yield
- YSXT N/A
- AVTX N/A
- EPS Growth
- YSXT N/A
- AVTX N/A
- EPS
- YSXT 0.21
- AVTX N/A
- Revenue
- YSXT $58,546,729.00
- AVTX $820,000.00
- Revenue This Year
- YSXT N/A
- AVTX N/A
- Revenue Next Year
- YSXT N/A
- AVTX N/A
- P/E Ratio
- YSXT $11.56
- AVTX N/A
- Revenue Growth
- YSXT 18.92
- AVTX N/A
- 52 Week Low
- YSXT $2.06
- AVTX $4.18
- 52 Week High
- YSXT $6.27
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- YSXT N/A
- AVTX 42.79
- Support Level
- YSXT N/A
- AVTX $7.42
- Resistance Level
- YSXT N/A
- AVTX $8.50
- Average True Range (ATR)
- YSXT 0.00
- AVTX 0.64
- MACD
- YSXT 0.00
- AVTX 0.02
- Stochastic Oscillator
- YSXT 0.00
- AVTX 17.16
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).